SpeeDx Pty Ltd, a Sydney, Australia-based developer of innovative clinical diagnostics to support improved patient outcomes, raised $15m in series B equity funding.
The round was led by Northpond Ventures.
The company intends to use the funds to continue to advance its pipeline.
SpeeDx specializes in molecular diagnostic solutions that go beyond simple detection to offer comprehensive information for improved patient management. Innovative real-time polymerase chain reaction (qPCR) technology has driven market-leading multiplex detection and priming strategies. Product portfolios focus on multiplex diagnostics for sexually transmitted infection (STI), antibiotic resistance markers, and respiratory disease.
The company is based in Australia with offices in Austin and London, and distributors across Europe.